Online citations, reference lists, and bibliographies.
← Back to Search

Anthracycline-related Cardiotoxicity In Childhood Cancer Survivors

S. Lipshultz, R. Karnik, Peter Sambatakos, V. Franco, S. Ross, T. Miller
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose of review Anthracyclines have markedly improved the survival rates of children with cancer. However, anthracycline-related cardiotoxicity is also well recognized and can compromise the long-term outcome in some patients. The challenge remains of how to balance the chemotherapeutic effects of anthracycline treatment with its potentially serious cardiovascular complications. Here, we review the pathophysiology, risk factors, clinical manifestations, prevention, and treatment of anthracycline-related cardiotoxicity. Recent findings Some risk factors and biomarkers associated with an increased probability of anthracycline-related cardiotoxicity have been identified. Modifying the structural forms and dosages of anthracyclines and coadministering cardioprotective agents may prevent some of these cardiotoxic effects. Cardiovascular complications have also been treated with angiotensin-converting enzyme inhibitors, &bgr;-blockers, and growth hormone replacement therapy. Cardiac transplantation remains the treatment of last resort. Summary Despite major advances in cancer treatment, anthracycline-related cardiotoxicity remains a major cause of morbidity and mortality in survivors of childhood cancer. Promising areas of research include: use of biomarkers for early recognition of cardiac injury in children receiving chemotherapy, development and application of cardioprotective agents for prevention of cardiotoxicity, and advancements in therapies for cardiac dysfunction in children after anthracycline treatment.
This paper references
10.1016/S1040-8428(97)10007-5
Anthracycline-induced cardiotoxicity in children and young adults.
A. Giantris (1998)
10.1016/j.ejca.2011.03.024
The use of liposomal anthracycline analogues for childhood malignancies: A systematic review.
E. Sieswerda (2011)
10.1016/0022-2828(91)90069-X
Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit.
A. Calderone (1991)
Cancer chemotherapy. In: Basic and clinical pharmocology
E Chu (2003)
10.1161/CIRCULATIONAHA.109.895771
Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function
A. De Angelis (2010)
10.1093/jnci/djn206
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
M. Ryberg (2008)
10.1200/JCO.2010.33.7907
Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.
S. Lipshultz (2012)
10.1074/jbc.M308033200
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes*
C. Lim (2004)
10.1007/s002800050048
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats
E. Herman (2000)
10.1067/MPD.2001.113045
Carvedilol as therapy in pediatric heart failure: an initial multicenter experience.
L. A. Bruns (2001)
Detection and monitoring of cardiotoxicity: what does modern cardiology offer? Support Care Cancer
R Jurcut (2008)
10.1007/s00280-009-1164-9
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
K. Thompson (2009)
A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.
C. Myers (1983)
10.1124/pr.56.2.6
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
10.1038/leu.2009.253
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)
L. Silverman (2010)
10.1254/JJP.76.405
Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae.
S. Takahashi (1998)
10.1080/01635581.2013.770042
Dietary Quality, Caloric Intake, and Adiposity of Childhood Cancer Survivors and Their Siblings: An Analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
David C. Landy (2013)
Cancer Facts & Figures 2004
P. Betts (2004)
Cardioprotective effects of dexrazoxane in children with acute lymphoblastic leukemia treated with doxorubicin: an overview
TM Lipincyzk (2005)
10.1016/j.bbrc.2008.11.059
Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.
Neil Ashley (2009)
10.1200/JCO.2001.19.10.2746
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
M. T. Meinardi (2001)
10.1002/cncr.22120
Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia
J. Gurney (2006)
10.1200/JCO.2010.33.4730
High risk of symptomatic cardiac events in childhood cancer survivors.
Helena J. van der Pal (2012)
10.1007/s00246-010-9878-3
Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer
B. Trachtenberg (2010)
10.2174/157339412800675342
Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Melissa B. Diamond (2012)
10.1016/j.pcad.2010.06.007
Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
D. Sawyer (2010)
10.1161/01.CIR.0000093196.59829.DF
Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy
D. Lebrecht (2003)
10.1097/01.COT.0000265629.30194.8E
Chronic health conditions in adult survivors of childhood cancer.
K. Oeffinger (2006)
Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia [abstract]. In: 5th World Congress of Pediatric Cardiology and Cardiac Surgery
S E Lipshultz (2009)
10.1056/NEJM199103213241205
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
10.1016/S1053-2498(98)00030-8
Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience.
R. Shaddy (1999)
10.1074/jbc.272.36.22800
A Novel Cardiac-Restricted Target for Doxorubicin
R. Jeyaseelan (1997)
Gender is a factor that can impact the severity of doxorubicin (DXR) toxicity in spontaneously hypertensive rats (SHR)
E. Herman (2008)
10.1097/01.npr.0000574500.05119.a4
The pediatric metabolic syndrome.
J. Morrison (2008)
10.1016/S0300-9084(02)00005-6
Peroxynitrite-induced inhibition and nitration of cardiac myofibrillar creatine kinase.
M. Mihm (2002)
10.1200/JCO.1988.6.6.976
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
G. Ambrosini (1988)
10.1200/JCO.2001.19.13.3173
Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries.
T. Möller (2001)
10.1007/s00280-008-0854-z
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
P. Thompson (2008)
Preventing and treating anthracycline-related cardio- toxicity in survivors of childhood cancer
M Diamond (2012)
10.1136/hrt.2007.136093
Anthracycline associated cardiotoxicity in survivors of childhood cancer
S. Lipshultz (2008)
10.1517/14656566.2013.804911
An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies
Patricia E. Zerra (2013)
10.1016/S1734-1140(09)70018-0
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
T. Šimůnek (2009)
10.1001/jama.2010.923
Long-term cause-specific mortality among survivors of childhood cancer.
R. Reulen (2010)
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia
LB Silverman (1985)
10.1200/JCO.2009.26.5751
Cardiotoxicity after childhood cancer: beginning with the end in mind.
S. Lipshultz (2010)
10.1542/peds.2012-0727
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
S. Lipshultz (2012)
10.1016/j.breast.2009.05.004
Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
R. Leonard (2009)
10.1096/fasebj.4.13.2210154
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
R. Olson (1990)
10.1200/JCO.2005.12.121
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
S. Lipshultz (2005)
10.1093/EURHEARTJ/16.SUPPL_F.38
Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
G. Feuerstein (1995)
This is the first book on this emerging late effect in survivors of childhood cancer
10.1016/j.jpeds.2011.08.018
Cardiovascular risk and insulin resistance in childhood cancer survivors.
J. Steinberger (2012)
10.1002/9780470514962.ch6
Obesity and cardiovascular disease.
A. Shaper (1996)
10.1023/A:1008365716693
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
10.1200/JCO.1999.17.7.2237
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
E. Herman (1999)
10.1016/S0006-2952(98)00307-4
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
D. Gewirtz (1999)
10.1081/CNV-200032899
Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies
A. Gabizon (2004)
10.1158/0008-5472.CAN-07-1649
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Y. Lyu (2007)
10.1007/s00431-013-1932-8
Cardiovascular disease in childhood: the role of obesity
Despina Herouvi (2013)
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
10.1016/S0024-3205(99)00362-8
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
H. Matsui (1999)
10.1124/MI.5.3.6
The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine.
X. Peng (2005)
10.1200/JCO.2007.14.9401
Anthracycline cardiotoxicity: from bench to bedside.
L. Gianni (2008)
10.1074/jbc.272.9.5828
Molecular Mechanisms of Doxorubicin-induced Cardiomyopathy
R. Jeyaseelan (1997)
10.1016/J.YJMCC.2004.05.024
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
P. Spallarossa (2004)
10.1002/pbc.24410
Exercise capacity in long‐term survivors of pediatric cancer: An analysis from the cardiac risk factors in childhood cancer survivors study
A. Miller (2013)
10.1007/s00520-007-0397-6
Detection and monitoring of cardiotoxicity—what does modern cardiology offer?
R. Jurcut (2007)
Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia [abstract
SE Lipshultz (2009)
10.1136/bmj.b4606
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
D. Mulrooney (2009)
10.1002/cncr.28256
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia
S. Lipshultz (2013)
10.1097/00001813-200402000-00011
Amifostine protection against doxorubicin cardiotoxicity in rats
V. Dragojević-Simić (2004)
10.1002/pbc.24017
Hospitalization rates among survivors of childhood cancer in the childhood cancer survivor study cohort
B. Kurt (2012)
10.1038/2171291a0
Cancer Chemotherapy
P. Alexander (1968)
10.1200/JCO.1998.16.2.545
Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
K. Nysom (1998)
10.1200/JCO.2008.19.7251
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia.
K. Oeffinger (2009)
10.1200/jco.1988.6.4.679
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
(1988)
10.1056/NEJMOA035153
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
S. Lipshultz (2004)
10.1016/J.YONC.2011.08.030
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
R. Arceci (2011)
10.1007/s12012-007-0005-5
Molecular and cellular mechanisms of anthracycline cardiotoxicity
B. Chen (2007)
10.1002/14651858.CD003917.pub3
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2008)
10.1073/PNAS.87.11.4275
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro.
H. Ito (1990)
10.1200/JCO.2010.30.3404
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Steven E. Lipshultz (2012)
10.1200/JCO.2002.12.102
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
S. Lipshultz (2002)
10.1016/S1470-2045(10)70204-7
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
S. Lipshultz (2010)
Long - term results of Dana - Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic
LB Silverman
10.1038/sj.bjc.6603288
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
S. Lowis (2006)
10.7326/0003-4819-96-2-133
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
10.1200/JCO.2008.20.2267
Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.
M. Tukenova (2010)
Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.
P. Calabro-Jones (1988)
Anthracycline-induced cardio- toxicity in children and young adults
A Giantris (1998)
Cardiotoxicity of cancer chemotherapy: implications for children
VC Simbre (2005)
10.1093/jnci/djn310
Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.
A. Mertens (2008)
Acute Lymphoblastic Leukemia protocol
(2002)
10.1161/01.CIR.98.12.1184
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.
P. Lechat (1998)
10.1542/peds.2004-1004
Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines
S. Lipshultz (2005)
10.1016/S0002-9149(97)00846-1
Mechanism of action of beta-blocking agents in heart failure.
M. Bristow (1997)
10.1016/j.ejca.2009.08.006
Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need?
G. Levitt (2009)
10.1016/j.ahj.2011.11.008
Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study.
David C. Landy (2012)
10.1016/0959-8049(95)00144-8
Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
R. Capizzi (1995)
10.1517/14656566.8.8.1039
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
E. Barry (2007)
10.1093/JNCI/83.15.1077
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
J. D. Cowan (1991)
10.1096/fj.03-0724rev
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
S. Fogli (2004)
10.1200/JCO.20.6.1677
Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
S. Lipshultz (2002)
10.1007/s00246-012-0539-6
Cranial Irradiation as an Additional Risk Factor for Anthracycline Cardiotoxicity in Childhood Cancer Survivors: An Analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
David C. Landy (2012)
10.1111/j.1365-2141.2005.05759.x
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
Karlijn A Wouters (2005)
10.1006/MGME.2000.3043
Molecular basis of anthracycline-induced cardiotoxicity and its prevention.
M. Horenstein (2000)



This paper is referenced by
10.1002/cam4.2713
Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee
T. Butel (2020)
10.1016/j.ijcard.2014.07.149
Cardiotoxicity: anthracyclines and long term cancer survivors.
S. Patanè (2014)
Title Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy
Y. Zhang (2015)
10.1007/s00246-018-1910-z
Two-Dimensional Speckle Tracking Echocardiography-Derived Strain Measurements in Survivors of Childhood Cancer on Angiotensin Converting Enzyme Inhibition or Receptor Blockade
Jamie K Harrington (2018)
10.1038/srep11235
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy
Y. Zhang (2015)
10.1007/978-3-319-43121-5_19
Treatment Effects and Long-Term Management of Sarcoma Patients and Survivors
L. Szalontay (2017)
10.1021/acs.chemrev.5b00116
Clinical Translation of Nanomedicine.
Y. Min (2015)
10.2459/JCM.0000000000000378
Pathophysiology of anthracycline cardiotoxicity
D. Mele (2016)
10.3892/mmr.2015.4234
Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting reactive oxygen species-activated extracellular signal-regulated kinase 1/2 in H9c2 cardiac myocytes.
Mi-Hua Liu (2015)
10.1152/ajpheart.00099.2014
The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.
M. Lindsey (2014)
10.3892/mmr.2015.4665
Resveratrol protects cardiomyocytes from doxorubicin-induced apoptosis through the AMPK/P53 pathway.
Mi-Hua Liu (2016)
10.1038/s41598-018-36721-5
Detection of anthracycline-induced cardiotoxicity using perfusion-corrected 99mTc sestamibi SPECT
Z. M. Safee (2019)
10.1056/NEJMRA1100265
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
J. Moslehi (2016)
10.1002/pbc.27499
Evaluation of cardiopulmonary exercise testing, heart function, and quality of life in children after allogenic hematopoietic stem cell transplantation
K. Vandekerckhove (2019)
10.1007/s12012-015-9327-x
Role of DNA Methylation on the Expression of the Anthracycline Metabolizing Enzyme AKR7A2 in Human Heart
Carrie C Hoefer (2015)
10.5935/ABC.2014S005
I DIRETRIZ DE INSUFICIÊNCIA CARDÍACA (IC) E TRANSPLANTE CARDÍACO, NO FETO, NA CRIANÇA E EM ADULTOS COM CARDIOPATIA CONGÊNITA, DA SOCIEDADE BRASILEIRA DE CARDIOLOGIA
E. Azeka (2014)
10.1016/j.msec.2017.12.024
pH-responsive mesoporous ZSM-5 zeolites/chitosan core-shell nanodisks loaded with doxorubicin against osteosarcoma.
F. Yang (2018)
Trial Designs Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy : Rationale and Design of the ERIC-ONC Study — A Single-Center , Blinded , Randomized Controlled Trial
Robin Chung (2016)
10.1007/s10555-020-09859-w
Cardiovascular diseases in survivors of childhood cancer
N. Bansal (2020)
10.3892/mmr.2015.4020
Hydrogen sulfide attenuates doxorubicin‑induced cardiotoxicity by inhibiting calreticulin expression in H9c2 cells.
Mi-Hua Liu (2015)
10.3892/ETM.2015.2693
Upregulation of peroxiredoxin III in doxorubicin-induced cytotoxicity and the FoxO3a-dependent expression in H9c2 cardiac cells.
Mi-Hua Liu (2015)
10.5772/67043
Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients
J. Kleinmahon (2017)
10.1007/978-1-0716-0668-1_8
Cardiac MRI Assessment of Mouse Myocardial Infarction and Regeneration.
Y. Wu (2021)
10.1007/s00018-018-2967-9
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma
Ilaria Buondonno (2018)
10.18632/oncotarget.15595
Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats
H. Ma (2017)
10.1007/s00109-016-1494-0
Doxorubicin-induced chronic dilated cardiomyopathy—the apoptosis hypothesis revisited
Cynthia Kankeu (2016)
Brain tumors: preclinical imaging and novel therapies
T. Lagerweij (2018)
10.1111/chd.12564
State of the art review: Chemotherapy‐induced cardiotoxicity in children
R. Loar (2018)
10.3171/2016.9.PEDS16152
Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
A. C. P. Sewing (2017)
10.1007/s00431-019-03477-7
Myocardial peak systolic velocity—a tool for cardiac screening of HIV-exposed uninfected children
Paula Martins (2019)
10.1007/s00059-020-04953-9
Common genetic predisposition for heart failure and cancer
T. Pfeffer (2020)
10.2217/pgs-2016-0036
Pharmacogenetics of anthracyclines.
J. Sági (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar